Insider · CIK 0001873253

Delfini Lisa

Reports to the SEC for 1 company · NEW HAVEN, CT

sec.gov

Transactions

Companies

Filings

CIK

0001873253

Forms 4 and 5

Insider transactions

41 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2025-05-31	TRVITrevi Therapeutics, Inc. · Performance Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+72K sh	—	—	110,400
2025-03-10	TRVITrevi Therapeutics, Inc. · Performance Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+38.4K sh	—	—	38,400
2025-02-18	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+226K sh	—	—	225,500
2025-01-08	TRVITrevi Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+5,000 sh	$0.51	+$2,555	64,660
2025-01-08	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−5,000 sh	—	—	42,125
2025-01-07	TRVITrevi Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+1,000 sh	$0.51	+$511	59,660
2025-01-07	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−1,000 sh	—	—	47,125
2024-05-22	TRVITrevi Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+16K sh	$0.51	+$8,197.973	57,629
2024-05-22	TRVITrevi Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−4,350 sh	$2.64	−$11.5K	53,279
2024-05-22	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−16K sh	—	—	48,125
2024-02-15	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+175K sh	—	—	175,000
2023-10-11	TRVITrevi Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,292 sh	$0.51	+$1,171.212	36,686
2023-10-11	TRVITrevi Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−785 sh	$2.02	−$1,585.7	35,901
2023-10-11	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,292 sh	—	—	64,168
2023-09-11	TRVITrevi Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,291 sh	$0.51	+$1,170.701	35,105
2023-09-11	TRVITrevi Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−711 sh	$2.20	−$1,564.2	34,394
2023-09-11	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,291 sh	—	—	66,460
2023-08-11	TRVITrevi Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,292 sh	$0.51	+$1,171.212	33,496
2023-08-11	TRVITrevi Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−682 sh	$2.36	−$1,609.52	32,814
2023-08-11	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,292 sh	—	—	68,751
2023-07-11	TRVITrevi Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,292 sh	$0.51	+$1,171.212	31,891
2023-07-11	TRVITrevi Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−687 sh	$2.34	−$1,607.58	31,204
2023-07-11	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,292 sh	—	—	71,043
2023-06-12	TRVITrevi Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,291 sh	$0.51	+$1,170.701	30,209
2023-06-12	TRVITrevi Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−610 sh	$2.64	−$1,610.4	29,599
2023-06-12	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,291 sh	—	—	73,335
2023-05-11	TRVITrevi Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,291 sh	$0.51	+$1,170.701	28,480
2023-05-11	TRVITrevi Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−562 sh	$2.89	−$1,624.18	27,918
2023-05-11	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,291 sh	—	—	75,626
2023-04-11	TRVITrevi Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,292 sh	$0.51	+$1,171.212	27,029
2023-04-11	TRVITrevi Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−840 sh	$1.84	−$1,544.76	26,189
2023-04-11	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,292 sh	—	—	77,917
2023-03-13	TRVITrevi Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+2,291 sh	$0.51	+$1,170.701	25,629
2023-03-13	TRVITrevi Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−892 sh	$1.75	−$1,563.854	24,737
2023-03-13	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−2,291 sh	—	—	80,209
2023-02-16	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+188K sh	—	—	187,500
2023-02-13	TRVITrevi Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+27.5K sh	$0.51	+$14.1K	31,812
2023-02-13	TRVITrevi Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−8,474 sh	$2.45	−$20.8K	23,338
2023-02-13	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−27.5K sh	—	—	82,500
2022-02-11	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+110K sh	—	—	110,000
2021-08-09	TRVITrevi Therapeutics, Inc. · Stock Option (right to buy)A Award	Chief Financial Officer	AAward	+100K sh	—	—	100,000

Recent filings

Accepted (ET)
Jun 34
Delfini Lisa0000950170-25-080886
SEC(opens sec.gov)
Mar 124
Delfini Lisa0000950170-25-037884
SEC(opens sec.gov)
Feb 204
Delfini Lisa0000950170-25-024111
SEC(opens sec.gov)
Jan 104
Delfini Lisa0000950170-25-004164
SEC(opens sec.gov)
May 244
Delfini Lisa0000950170-24-064598
SEC(opens sec.gov)
Feb 164
Delfini Lisa0000950170-24-016458
SEC(opens sec.gov)
Oct 124
Delfini Lisa0001209191-23-052687
SEC(opens sec.gov)
Sep 134
Delfini Lisa0001209191-23-049252
SEC(opens sec.gov)
Aug 144
Delfini Lisa0001209191-23-045595
SEC(opens sec.gov)

Companies

Trevi Therapeutics, Inc.Chief Financial OfficerTRVI

Address

C/O TREVI THERAPEUTICS, INC. 195 CHURCH STREET, 16TH FLOOR

NEW HAVEN, CT, 06510